Ontology highlight
ABSTRACT:
SUBMITTER: Blay JY
PROVIDER: S-EPMC8383051 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
Blay Jean-Yves JY Serrano César C Heinrich Michael C MC Zalcberg John J Bauer Sebastian S Gelderblom Hans H Schöffski Patrick P Jones Robin L RL Attia Steven S D'Amato Gina G Chi Ping P Reichardt Peter P Meade Julie J Shi Kelvin K Ruiz-Soto Rodrigo R George Suzanne S von Mehren Margaret M
The Lancet. Oncology 20200605 7
<h4>Background</h4>Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge for patients with advanced gastrointestinal stromal tumours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumours.<h4>M ...[more]